Cerus Corp (NASDAQ:CERS) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET
Company Participants
Joel Trujillo - Senior Director, IR
William Greenman - President, CEO & Director
Vivek Jayaraman - COO
Kevin Green - VP, Finance & CFO
Carol Moore - SVP, Regulatory Affairs, Quality & Clinical
Conference Call Participants
Mathew Blackman - Stifel, Nicolaus & Company
Jacob Johnson - Stephens Inc.
Brandon Folkes - Cantor Fitzgerald
Joshua Jennings - Cowen and Company
Operator
Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Joel Trujillo, Cerus' Senior Director of Investor Relations. Please go ahead.
Joel Trujillo
Thank you, and good afternoon. I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Kevin Green, Cerus' Chief Financial Officer; Dr. Laurence Corash, Cerus' Chief Scientific Officer; Vivek Jayaraman, Cerus' Chief Operating Officer; and Carol Moore, Cerus' Senior Vice President of Regulatory Affairs and Quality.
Cerus issued a press release today announcing our financial results for the fourth quarter and year ended December 31, 2022, describing the company's recent business highlights. You can access a copy of this announcement on the company's website at www.cerus.com. I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our 2023 product revenue guidance and goals, operating expenses, anticipated cash used from operations, gross profit and gross margins as well as commercial development efforts, future growth and growth strategy, future product sales, product launches, ongoing and future clinical trials, ongoing and future product development and our regulatory initiatives, including the timing of these events and activities. These forward-looking statements involve risks and uncertainties that could cause actual events, performance and results to differ materially. They are identified and described in today's press release and under Risk Factors in our Form 10-K for the year ended December 31, 2022, which we will file shortly. We undertake no duty or obligation to update our forward-looking statements.